ANN ARBOR, Mich., Aug 26, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) announces the following Webcast:

What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2008 Investor Conference Call

When: Friday, August 29, 2008 @ 11:00 am (EDT)

Where: http://www.investorcalendar.com/IC/CEPage.asp?ID=133137

How: aEURc For live Internet access, simply log on to the web at the address above.

aEURc For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054.

aEURc To download the podcast, simply log on to the web at the address above.

Contact: Investor Relations Department, (734) 930-5777 or mail@aastrom.com

If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ until November 30, 2008. Through September 12, 2008, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 293771.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applications of the technology to cardiac and vascular regeneration. The company currently has a cardiovascular regeneration product in Phase II development for the treatment of dilated cardiomyopathy (DCM) (called the IMPACT-DCM trial) and critical limb ischemia (called the RESTORE-CLI trial).

For more information, visit Aastrom's website at www.aastrom.com. (astmc)

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. 
Investor Relations Department, 734-930-5777 or 
mail@aastrom.com

Copyright Business Wire 2008

News Provided by COMTEX